Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial

J A M Anderson, J Hirsh, S Yusuf, M Johnston, R Afzal, S R Mehta, K A A Fox, A Budaj, J W Eikelboom

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

In the OASIS-5 trial, fondaparinux reduced major bleeding with similar short-term efficacy as enoxaparin but lowered death and stroke during long-term follow-up. The mechanism of lower bleeding and improved efficacy with fondaparinux is uncertain.
Original languageEnglish
Pages (from-to)243-9
Number of pages7
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number2
DOIs
Publication statusPublished - 2010

Keywords / Materials (for Non-textual outputs)

  • anticoagulants
  • hemorrhage
  • heparin
  • myocardial infarction

Fingerprint

Dive into the research topics of 'Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial'. Together they form a unique fingerprint.

Cite this